ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.27
-0.99 (-4.89%)
Mar 31, 2025, 1:23 PM EDT - Market open
ADMA Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 22.5, with a low estimate of 14 and a high estimate of 26. The average target predicts an increase of 16.76% from the current stock price of 19.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +29.74% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +34.92% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +29.74% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -6.59% | Oct 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | +3.79% | Sep 20, 2024 |
Financial Forecast
Revenue This Year
495.47M
from 426.45M
Increased by 16.18%
Revenue Next Year
613.97M
from 495.47M
Increased by 23.92%
EPS This Year
0.71
from 0.81
Decreased by -12.80%
EPS Next Year
0.94
from 0.71
Increased by 33.57%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 520.6M | 703.5M | 862.5M | ||
| Avg | 495.5M | 614.0M | 737.2M | ||
| Low | 465.9M | 529.5M | 590.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.1% | 42.0% | 40.5% | ||
| Avg | 16.2% | 23.9% | 20.1% | ||
| Low | 9.2% | 6.9% | -3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.76 | 1.14 | 1.52 | ||
| Avg | 0.71 | 0.94 | 1.18 | ||
| Low | 0.66 | 0.82 | 0.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -6.7% | 62.0% | 61.4% | ||
| Avg | -12.8% | 33.6% | 25.0% | ||
| Low | -18.9% | 16.5% | 0.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.